Dengue vaccine development and dengue viral neutralization and enhancement assaysXia Jin, Olivia Tono Block, Robert Rose, Jacob Schlesinger
Corresponding author name: Xia Jin
Corresponding author e-mail: email@example.com
Citation: Antiviral Therapy 2009; 14:739-749
Date published online: 08 October 2009
Dengue fever is a major tropical infectious disease that affects 50–100 million people each year. Its complications, namely dengue haemorrhagic fever and dengue shock syndrome, disproportionately afflict children and young adults. The primary goal of several vaccines now in development is to elicit protective neutralizing antibody responses; however, the exact definition of such responses remain unclear. Here, we review briefly the historical aspects of dengue vaccine development and current candidate dengue vaccines, and discuss various laboratory assays for gauging the neutralizing antibody responses to infection or vaccination, or both. We conclude that modification of current neutralization assays is required to improve the correlation between neutralization end point determinations and protection against secondary heterotypic dengue infections.